Literature DB >> 9202015

Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase.

G R Upchurch1, G N Welch, A J Fabian, J E Freedman, J L Johnson, J F Keaney, J Loscalzo.   

Abstract

Hyperhomocyst(e)inemia is believed to injure endothelial cells in vivo through a number of mechanisms, including the generation of hydrogen peroxide (H2O2). Earlier in vitro studies demonstrated that homocyst(e)ine (Hcy) decreases the biological activity of endothelium-derived relaxing factor and that this decrease can be reversed by preventing the generation of hydrogen peroxide. Here we show that Hcy treatment of bovine aortic endothelial cells leads to a dose-dependent decrease in NOx (p = 0.001 by one-way analysis of variance) independent of endothelial nitric-oxide synthase activity or protein levels and nos3 transcription, suggesting that Hcy affects the bioavailability of NO, not its production. We hypothesized that, in addition to increasing the generation of H2O2, Hcy decreases the cell's ability to detoxify H2O2 by impairing intracellular antioxidant enzymes, specifically the intracellular isoform of glutathione peroxidase (GPx). To test this hypothesis, confluent bovine aortic endothelial cells were treated with a range of concentrations of Hcy, and intracellular GPx activity was determined. Compared with control cells, cells treated with Hcy showed a significant reduction in GPx activity (up to 81% at 250 microM Hcy). In parallel with the decrease in GPx activity, steady-state GPx mRNA levels were also significantly decreased compared with control levels after exposure to Hcy, which appeared not to be a consequence of message destabilization. These data suggest a novel mechanism by which Hcy, in addition to increasing the generation of hydrogen peroxide, may selectively impair the endothelial cell's ability to detoxify H2O2, thus rendering NO more susceptible to oxidative inactivation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9202015     DOI: 10.1074/jbc.272.27.17012

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  111 in total

1.  Hyperhomocysteinemia in patients with Behçet's disease: is it due to inflammation or therapy?

Authors:  Zeki Yesilova; Salih Pay; Cagatay Oktenli; Ugur Musabak; Kenan Saglam; S Yavuz Sanisoglu; Kemal Dagalp; M Kemal Erbil; Ismail H Kocar
Journal:  Rheumatol Int       Date:  2004-04-01       Impact factor: 2.631

2.  Chronic mild hyperhomocysteinemia alters ectonucleotidase activities and gene expression of ecto-5'-nucleotidase/CD73 in rat lymphocytes.

Authors:  Emilene B S Scherer; Luiz Eduardo B Savio; Fernanda C Vuaden; Andréa G K Ferreira; Maurício R Bogo; Carla D Bonan; Angela T S Wyse
Journal:  Mol Cell Biochem       Date:  2011-11-02       Impact factor: 3.396

3.  H2S regulation of nitric oxide metabolism.

Authors:  Gopi K Kolluru; Shuai Yuan; Xinggui Shen; Christopher G Kevil
Journal:  Methods Enzymol       Date:  2015-01-17       Impact factor: 1.600

Review 4.  Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention.

Authors:  Maureen McMahon; Bevra H Hahn; Brian J Skaggs
Journal:  Expert Rev Clin Immunol       Date:  2011-03       Impact factor: 4.473

5.  Methylenetetrahydrofolate reductase gene polymorphism, homocysteine and risk of macroangiopathy in Type 2 diabetes mellitus.

Authors:  J Sun; Y Xu; Y Zhu; H Lu
Journal:  J Endocrinol Invest       Date:  2006-10       Impact factor: 4.256

Review 6.  Molecular targeting of proteins by L-homocysteine: mechanistic implications for vascular disease.

Authors:  Alla V Glushchenko; Donald W Jacobsen
Journal:  Antioxid Redox Signal       Date:  2007-11       Impact factor: 8.401

7.  Overexpression of cellular glutathione peroxidase rescues homocyst(e)ine-induced endothelial dysfunction.

Authors:  N Weiss; Y Y Zhang; S Heydrick; C Bierl; J Loscalzo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

8.  The nutrigenetics of hyperhomocysteinemia: quantitative proteomics reveals differences in the methionine cycle enzymes of gene-induced versus diet-induced hyperhomocysteinemia.

Authors:  Patricia M DiBello; Sanjana Dayal; Suma Kaveti; Dongmei Zhang; Michael Kinter; Steven R Lentz; Donald W Jacobsen
Journal:  Mol Cell Proteomics       Date:  2009-12-14       Impact factor: 5.911

9.  Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson's disease.

Authors:  Eliseu Felippe dos Santos; Estela Natacha Brandt Busanello; Anelise Miglioranza; Angela Zanatta; Alethea Gatto Barchak; Carmen Regla Vargas; Jonas Saute; Charles Rosa; Maria Júlia Carrion; Daiane Camargo; André Dalbem; Jaderson Costa da Costa; Sandro René Pinto de Sousa Miguel; Carlos Roberto de Mello Rieder; Moacir Wajner
Journal:  Metab Brain Dis       Date:  2009-03-18       Impact factor: 3.584

10.  Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia.

Authors:  Sanjana Dayal; Roman N Rodionov; Erland Arning; Teodoro Bottiglieri; Masumi Kimoto; Daryl J Murry; John P Cooke; Frank M Faraci; Steven R Lentz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-06-20       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.